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INTRODUCTION  
Japan is the second largest pharmaceutical market  behind the 
United States and a h ighly developed country. It has been 
discovered that Japanese people are using multiple drugs 
with an especially high use of recently approved drugs. The 
patient awareness is now similar to that in the Western 
countries. Medicinal products represent over 20% of 
healthcare costs with about almost 50% in elderly patients. 
Therefore Japan becomes more and more attractive for the 
pharmaceutical industry.  
One of the biggest hurdles for the government is the “drug 
lag” problem, whereby many new innovative medicinal 
drugs do not reach the Japanese market until several years 
after the United States (US) and Europe (EU). This delay is 
caused due to the obligation to perform clinical bridging 
studies in Japan hand since clinical data obtained in non-
Japanese trials such as EU and US studies cannot solely be 
used to obtain market approval in Japan. On the other hand 
there are long rev iew periods for clinical trial applications 
and marketing applications. To min imize this “drug lag” the 
Japanese government is encouraging pharmaceutical 
companies to conduct simultaneous clinical development and 
include Japan in global clin ical trials. Pharmaceutical 
companies also want to develop medicinal products more or 
less in parallel in the major markets of the US, EU and Japan 
even this aspect is driven by more commercial 
considerations. Once the clinical development program is 
fin ished and all data are compiled the dossier has  to be 
created to be filed with the respective authorities.  
 
 
To simplify the general life cycle management a harmonized  
dossier approach would be of advantage. A harmonized  
dossier is easier to handle since the same document can be 
used for all countries . It also facilitates the compliance of the 
documentation, increases the supply flexib ility and facilitates 
the communicat ion between external and internal regulatory 
communicat ion units. Once the marketing authorization is 
granted variations (clinical or quality based) or extension 
applications update of one dossier is faster than different 
dossiers.  
MHLW: 
The Ministry of Health, Labor and Welfare (MHLW) is 
regulatory authority of the pharmaceutical regulatory affairs 
in Japan. Formal approvals and licens es are required  to 
market ing drugs in Japan which are obtained from the 
MHLW.  
The MHLW  was established in January 2001 as part  of the 
government program for reorganizing government ministries. 
One of the 11 bureaus of the MHLW is the Pharmaceutical 
and Food Safety Bureau (PFSB). This bureau handles 
clin ical studies, approval reviews and post-marketing safety 
measures. 
Functions of MHLW: 
 To give a marketing approval.  
 To issue a license for marketing authorization holder.  
 To issue a manufacturer license 
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PHARMACEUTICALS AND MEDICAL DEVICES 
AGENCY (PMDA): 
 The PMDA (KIKO) was established in April 2004, through 
the integration of the Pharmaceutical and Medical Devices 
Evaluation Center in the National Institute of Health 
Sciences, the OPSR, and part of the Medical Devices Center, 
and the PMDA started handling all consultation and review 
work from the preclin ical stage to approvals and post-
market ing surveillance.  
The work of the PMDA can be divided into following 
categories:  
 ADR relief work: Collection, examination and analysis, 
assessment & provision of ADR informat ion 
 Review and Implementation of works, such as 
examination, data analysis, etc. before admin istrative 
measures eg. 
 Scientific review of Pharmaceuticals and Medical 
Devices application, 
 GLP/GCP/GMP/QMS inspection,  
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 Clin ical trial consultation  
The PMDA consists of 22 offices and 2 groups as follows: 
the Office of General Affairs, Office o f Financial 
Management, Office of Planning and Coordination, Office of 
Regulatory Science, Office of International Pro jects and 
Office o f International Liaison, Office of Relief Funds, 
Office of Review Administration, Office of Review 
Management, Office of New Drug I, Office of New Drug II, 
Office of New Drug III, Office of New Drug IV, Office of 
New Drug V, Office of Biologics I, Office of Bio logics II, 
Office of OTC and Generic Drugs, Office of Medical 
Devices I, Office of Medical Devices II, Office of 
Conformity Audit, Office of Safety I, Office of Safety II, 
Office o f Compliance and Standards Officer,  
Subjects of GMP Inspection by PMDA  
 Domestic manufacturing sites which are manufacturing 
following products; 
 New drugs 
 Biological Products 
 Products derived from human b lood and human 
plasma 
 Vaccines 
 Tissue-based pharmaceuticals  
 Radiopharmaceuticals  
 Biotechnology-products 
 Foreign manufacturing sites1,2,3,4, 5 
PHARMACEUTICAL AFFAIRS LAW: 
The objective of the Pharmaceutical Affairs Law is to 
improve public health through regulations required to assure 
the quality, efficacy, and safety of drugs, quasi-drugs, 
cosmetics, and medical devices, and through measures to 
promote R&D of d rugs and medical devices that are 
especially essential for health care.  
Manufacturing and marketing medical devices are regulated 
by the Pharmaceutical Affairs Law (PAL). The current PAL 
came into effect in April 2005 after the rev ision of the 
Pharmaceutical 
Affairs Law was promulgated in 2002. The revision has been 
undertaken from the viewpoint of international regulatory 
consistency. Namely,  
(a) Substantial reforms of safety measures for medical 
devices,  
(b) Revision of the approval and licensing system and 
enhancement of post marketing safety measures, 
 (c) Enhancement of safety measures of biological products. 
This report highlights the above revised points and explains 
procedures for manufacturing and marketing medical devices 
in connection with PAL.
6, 7 
Medical device:  
An instrument or apparatus intended for use diagnosing, 
curing, or preventing diseases in humans or an imals, or 
intended to affect the structure or functions of the bodies of 
humans or animals. 
Classification:  
(1) General medical devices: these are ext remely low risk 
devices and market ing approval not required.  
(2) Controlled  medical devices: these are low risk devices 
and  third party certification required 
(3) Specially controlled medical devices: these are high 
risk medical devices and market ing approval required.  
LICENS E FOR MARKETING AUTHORIZATION: 
 Drug Marketing Approvals:  
Drug marketing approval refers to governmental permission 
for a drug with the quality, efficacy, and safety or a drug that 
is manufactured by a method in compliance with 
manufacturing control and quality control standards based on 
an appropriate quality and safety management  system, 
generally distributed, and used for healthcare in Japan.  
A GMP compliance review is performed to assure that the 
plant manufacturing the product complies with the 
manufacturing control and quality control standards. 
Marketing approval is granted to products meeting these 
standards. This approval system is the essential basis for 
ensuring good quality, efficacy, and safety of drugs and 
related products, which is the principal objective of the 
Pharmaceutical Affairs Law.  
The Pharmaceutical Affairs Law of Japan requires a license 
for marketing authorization when importing to  Japan and 
selling pharmaceutical products manufactured in other 
countries. 
To receive a license for market ing authorizat ion, the 
manufacturer/seller must, at the very least, employ the 
following personnel full t ime: a General Manufacturing and 
Marketing Officer, a Quality Assurance Officer, and a Safety 
Management Officer.  
A license for market ing authorizat ion may not be granted if 
the quality management methods  and post market ing safety 
management methods applied with respect to the 
pharmaceutical product fail to conform to the standards 
stipulated in the ordinances promulgated by the Ministry of 
Health, Labour and Welfare. Licenses for market ing 
authorization are granted by the prefectural government for 
the location of the office where the General Manufacturing 
and Marketing Officer is stationed.  
Manufacturing License:  
When manufacturing pharmaceuticals in  Japan, each 
manufacturing location requires a manufacturing license. As 
a condition to receiving a manufacturing license, there must 
be a fu ll-time pharmacologist in each manufacturing location 
who serves as the Pharmaceuticals Manufacturing Manager 
(Managing Pharmacist). In addit ion, the structure and 
facilit ies at the location must satisfy criteria stipulated in the 
ordinances promulgated by the Ministry of Health, Labor and 
Welfare.  
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The manufacturing license is issued by the governor of the 
prefecture in which the manufacturing location is located 
except in cases requiring part icularly high levels of expert ise. 
To manufacture pharmaceutical products, a license for 
market ing authorization holder must also obtain a 
manufacturing license. A license for marketing authorizat ion 
holder may entrust all manufacturing of the pharmaceutical 
product to a third party, but the party entrusted with 
manufacture must obtain a manufacturing license. Parties 
that receive manufacturing licenses may be held criminally  
accountable and/or may be subject to admin istrative 
disposition, including cancellat ion of licenses, in the event of 
violations of the Pharmaceutical Affairs Law.  
Accreditation of Foreign Manufacturers:  
The Pharmaceutical Affairs Law stipulates that when 
pharmaceutical products are manufactured in other countries 
for export to Japan, the foreign manufacturer may receive 
accreditation from the Min ister of Health, Labor and Welfare 
for each foreign location at which pharmaceutical products 
are manufactured, and in actual practice, foreign 
manufacturers are required to obtain this accreditation. 
Manufacture and Sale Approval: 
Parties engaged in manufacture/sale must in principle receive 
the approval of the Minister of Health, Labor and Welfare for 
the manufacture and sale of each pharmaceutical product to 
be manufactured and sold (including import sales) in Japan. 
Notwithstanding, approval may be revoked in the event of 
problems with the efficacy or safety of a pharmaceutical 
product after it has been approved. 
Exceptional Approvals for Foreign Countries: 
 Under the Pharmaceutical Affairs Law, enterprises located 
in foreign countries may apply for manufacture and sale 
approval from outside of Japan. For example, a foreign 
pharmaceuticals manufacturer who wishes to obtain approval 
for  manufacture and sale in Japan may no minate a party to 
conduct manufacture/sale in  Japan and seek approval from 
the Minister of Health, Labor and Welfare for manufacture 
and sale by that party. The party nominated to manufacture 
and sell the pharmaceutical must obtain a license for 
market ing authorization and must discharge all 
responsibilit ies as a manufacturer/seller.  
Post marketing Safety: 
The pharmaceutical manufacturer/seller and the party 
obtaining approval under foreign country exceptions are 
required under the Pharmaceutical Affairs La w to collect and 
investigate information on side effects and infections 
resulting from the pharmaceutical product.  
Reports must be filed  with the Minister o f Health, Labor and 
Welfare in the event that an objective assessment of the 
informat ion obtained indicates that the pharmaceutical 
product meets certain criteria stipulated in the ord inances 
promulgated by the Ministry of Health, Labor and Welfare.
7, 
8, 9 
JAPAN NEW DRUG APPLICATION (J-NDA) 
PROCEDURE:  
The pharmaceutical administration in Japan consists of 
various laws and regulations of which the Pharmaceutical 
Affairs Law (PAL) is a fundamental one consisting of 11 
chapters and 91 art icles.  
Various regulations apply to the development, manufacture, 
import, marketing and proper use of drugs exists. Some of 
the main regulat ions affecting pharmaceuticals are listed 
below:  
 Quality standards and government standards e.g. 
Japanese Pharmacopeia (JP)  
 Classification of drugs e.g. biological products and 
specified biological products  
 Concerning marketing approvals e.g. revision in April 
2005  
 GMP status e.g. GMP cert ificate as prerequisite to 
obtain a manufacturing business license  
 Accreditation of overseas manufacturers e.g. 
accreditation is required to export  medicinal products 
from overseas to Japan  
 GLP and GCP standards  
 Good Quality Practice (GQP) on marketed products  
 Good Vigilance Pract ice (GVP) on marketed products 
etc.  
Pre-submission Activities  
Consultation Meetings  
In Japanese culture it  is uncommon to make decisions during 
consultation meet ings based on information, which is 
exchanged in this same meeting by means of discussion or 
presentation. Usually, in Japan decisions are either made 
prior to a meet ing based on available informat ion or, 
alternatively, the final decision is taken after the meeting. In  
case the decision is taken prior to the meeting the outcome is 
then basically  only exp lained during the meeting. Therefore 
it is recommended to provide a strategy which allows 
influencing the thinking of the PMDA prior to the meeting. 
Prior to the official consultation meeting pre-meetings are 
taking place to discuss the content of the dossier in advance 
for rev iew. In 2005 the activit ies of the PMDA consultation 
meet ing were evaluated to review the t imelines of such 
meet ings. New shorter timelines were determined which  
were again revised in 2008.  
Approval Procedure  
The PAL’s princip le objective is to provide an approval 
system which ensures good quality, efficacy and safety of the 
medicinal products to be marketed and used for healthcare in  
Japan. 
The approval review process consists of the following steps:  
 J-NDA evaluation process  
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 Compliance Review (including GCP inspection)  
 GMP inspection (can also be performed as paper audit)  
Priority Review Designation  
NDA approvals reviews are normally p rocessed in the order 
the application forms are received. For medicinal products 
considered to be especially important from a medical 
standpoint such as new drugs treating serious diseases and 
meet ing especially high medical need, priority review can be 
granted (for orphan drugs priority review is automatically  
granted).  
Criteria for priority review are severity of the target 
indication (disease with important effect on patient’s survival 
(fatal disease), progressive and irreversible d isease with 
marked  effect on daily  life) and medical efficacy (no existing 
treatments available, superior to currently available therapies 
with regard to efficacy, safety and quality of life).  
Products of priority review are given priority at  each stage of 
the review process as much as possible. The process of the 
MHLW could therefore be shortened from 12 months to 6 
months which results in a total of 12 – 18 months approval 
period. When a drug product subject to priority review is 
approved this fact is made public.  
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Accreditation: 
A foreign manufacturer who intends to export medicinal 
drugs into Japan is required to be accredited by the MHLW  
as an “Accredited Foreign Manufacturer”. The applicant is 
required to submit an “Application for Accreditation” that is 
addressed to the minister and an  “Application for 
Accreditation Examination” to the chief executive of the 
PMDA (16). Among the documents which have to be 
attached to the accreditation application (all documents have 
to be translated into Japanese) is a medical cert ificate from a 
physician which indicates whether or not the applicant (e.g. 
the CEO of a company) has mental disorders or is addicted to 
narcotics, cannabis, and opium or stimulant drugs. The 
application should be submitted at latest when the NDA is 
submitted. The accreditation process takes about 5 months. 
The accreditation needs to be renewed every 5 years.  
Post Authorization Activities:  
Information concerning the new drug approval prepared fo rm 
the review data (final evaluation report) is p laced on the 
website of the PMDA so that accurate informat ion 
concerning the quality, efficacy and safety obtained during 
the approval review process is supplied to the medical 
institutions.  
The PMDA request the applicant to provide a masking 
proposal of the evaluation report and a masking proposal for 
the data that summarizes non-clin ical and clin ical results. 
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Masking of quality data is not necessary since they are not 
included in such publication report. Informat ion related to 
the quality of the medicinal product is provided in the 
informat ion to the doctors. The summary data should be 
published within 3 months after approval at the latest.
10, 11
 
DATA REQUIRED FOR APPROVAL OF 
APPLICATIONS (DOSSIER CREATION): 
The dossier has to be created according to the ICH guideline 
for Common Technical Documents (CTD) and fo llows the 
CTD structure. Therefore the dossier exists of Module 2 with 
the summary documents for quality, non-clin ical and clinical, 
Module 3 including the quality data, Module 4 the non-
clin ical data and Module 5 the clin ical data, respectively. In  
addition regional informat ion e.g. labeling information is 
provided in Module 1.  
In Japan Module 3, 4 and 5 can be submitted in English 
whereas Module 1 and 2 have to be translated into Japanese. 
Module 1 contains in Japan the so called “Application 
Approval Form” (AAF) listing product formulation, relevant 
manufacturing information, shelf life and storage condition 
as well as the specification and test methods. 
 Module 1 
Module 1 contains the following information:  
 NDA applicat ion form (including AAF and position 
paper for priority review, if applicab le) 
 Cert ificates (GLP, GCP statements, expert statements) 
 Patent status information 
 Discovery, research and development history 
 Conditions of use in foreign countries (including 
labeling information) 
 List of other drugs with similar pharmacological action  
 Draft package insert  
 Documentation of non-proprietary name  
 Summary of data on designation e.g. powerful drug  
 Draft p rotocol for post-market ing surveillance  
 List of attached documents (Module 3, 4 and 5)  
  Others:  
 Application form for accred itation and registration 
of foreign manufacturers  
 Application form for GMP inspection  
 List of laboratories conducting GLP studies  
 GCP compliance report  
 Application form for document review  
Application Approval Form (AAF)  
The AAF describes critical aspects of the drug. It is attached 
to the license upon approval. The “approved” items 
described are binding. They determine a regulatory 
commitment and are the basis of post-approval changes. 
Topics which are not mentioned in the AAF may be changed 
without regulatory consequence. 
The AAF contains the following in formation:  
 General information as required e.g. name, dosage and 
administration, use or indication, storage method and 
shelf life, specificat ions and test methods, 
manufacturing facility, drug substance facility  
 Information about ingredients and content 
Composition: amount of excipients and specifications 
(JP)  
  Specifications and test methods  
  Reference substance  
  Manufacturing methods  
 Manufacturing facility -Drug substance manufacturer, 
Drug product manufacturer, External testing facilit ies. 
 
Information listed in the AAF should be a summary of the 
informat ion in the QOS e.g. manufacturing description and 
in-process controls and test methods. The information is 
provided in special format  as provided by the PMDA. 
Summary tables and figures should be included with very 
brief narratives of the information provided in the QOS. In  
the manufacturing description the items applicable to minor 
change notification or partial change application have to be 
highlighted. On the other hand, specifications and test 
methods in the AAF should be a copy of the description in 
the QOS.  
 Module 2 (QOS)  
(1) Modules 2 to 5 (CTD) table of contents 
(2) CTD introduction 
(3) Quality overall summary 
(4) Nonclin ical overv iew 
(5) Clin ical overv iew 
(6) Nonclin ical summary (text and tables) 
 Pharmacology 
 Pharmacokinetics 
 Toxicity 
(7) Clin ical summary  
 Summary of bio pharmaceutics and associated analytical 
methods 
 Summary of clinical pharmacology studies 
 Summary of clinical efficacy 
 Summary of clinical safety 
 Literature references 
 Synopses of individual studies 
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The QOS of Module 2 is the main  review document for the 
PDMA. In Japan it is expected that the applicant summarizes 
all critical data from Module 3 together with a sufficient 
discussion on every critical point for ensuring the quality of 
the medicinal product. The QOS should be written in a way  
that it makes it possible for the reviewer to understand the 
characteristics of the drug within a short time and to review 
the J-NDA application efficiently.  
The QOS should include many figures and tables which 
summarize the critical data. It contains more detailed  
informat ion The Pharmaceutical Manufacturers Association 
of Tokyo, Osaka Pharmaceutical Manufacturers Association 
and Japan Health Sciences Foundation issued in July 2002 a 
Mock-up of the Japanese QOS. This document can be used 
for the dossier preparation. Since companies also intend to 
prepare global dossiers which are applicable for ICH as well 
as Non-ICH countries the mock-up document can provide 
specific Japanese requirements which need to be 
incorporated. Since the QOS in Japan contains more detailed  
informat ion compared to the QOS for the EU and US a 
separate QOS has to be prepared which generally  contains 
much more than 100 pages. Writing the QOS in Japanese 
style facilitates the review process.  
Items listed in the manufacturing process description require 
appropriate change control and are either subject to partial 
change application or minor change notification. Partial 
change application requires review and approval of the 
PMDA which  could take 12-18 months. Minor change 
notification follows the princip le of do and tells (within 30 
days). Therefore it has to be carefully considered which  
items should be highlighted as partial change applicat ion and 
which as minor change notification.  
3) Module 3: Quality 
(1) Module 3 table of contents 
(2) Data or reports 
(3) Literature references 
4) Module 4: Nonclin ical study reports 
(1) Module 4 table of contents 
(2) Study reports 
(3) Literature references 
5) Module 5: Clin ical study reports 
(1) Module 5 table of contents 
(2) Tabular listing of all clinical studies 
(3) Clin ical study reports 
(4) Literature references 
12, 13, 14,15,16,17
 
REQUIREMENTS FOR DRUG MANUFACTURING 
AND MARKETING APPROVALS: 
Proper control at the stage of drug manufacture is essential so 
that drugs can be supplied to patients with good quality. Th is 
means that the manufacturers and the buildings and facilit ies 
in the manufacturing plants must be appropriate so that drugs 
based on the approvals can be produced.  
The manufacturing process as a whole must be controlled on 
the basis of scientific princip les, and it is also necessary to 
assure the quality of drugs manufactured by taking measures 
to prevent errors during processing. When it is not found that 
the methods of manufacturing control or quality control at a  
manufacturing p lant conform to the standards, the Minister 
of Health, Labour and Welfare cannot grant a manufacturing 
and marketing license. And when the buildings and facilit ies 
of a manufacturing plant do not conform to the standards, the 
Minister of Health, Labor and Welfare or prefectural 
governor can choose not to grant a license.  
The requirements for manufacturing control and quality 
control methods for drug substance should be referred to the 
Guidelines on GMP for Drug Substance (ICH Q7A, currently  
Q7) which concretely specifies 20 requirements concerning 
manufacturing  and control of drug  substance, including 
quality control, buildings and facility, validation, as agreed in  
the ICH5 held in San Diego, California, USA in  November 
2000. The following sections outline the GMP regulations: 
1) Required documentation: 
According to the GMP regulation, all of the operations in  the 
plants must be divided into operations for manufacturing 
control and those for quality control, and various types of 
documentation are required, including standard operating 
procedures for standardization of all work conditions (drug 
product standards, manufacturing control standards, 
manufacturing hygiene control standards and quality control 
standards), documentation required for actual operation 
procedures based on these standards (manufacturing 
instructions and test and self-inspection protocols), records 
of the results of all of these operating procedures (records 
related to manufacture, records of manufacturing hygiene 
control, and records of tests and self-inspections), and 
records of storage and distribution.  
Additional documents should be compiled if they are 
considered necessary for proper manufacturing control and 
quality control. These documents must be retained for 
designated time periods from the date of preparat ion. When 
damage to the health of patients or other users of biological 
products (biotechnological technology-derived and of 
biological o rig in) occurs, records must be retained for the 
period required to clarify the cause of this damage.  
2) Personnel organization: 
All operations in manufacturing plants are subject to 
manufacturing control and quality control based on standard 
operating procedures as described previously, and the 
managers in each d ivision used to bear responsibility for 
these operating procedures, but this now lies with the quality 
control unit. The final responsibility for deciding whether or 
not drugs should be shipped and that for solving problems 
related to overall manufacturing control and quality control 
in the plant lies with the drug manufacturing control manager 
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designated in each plant under the Pharmaceutical Affairs 
Law. 
3) Manufacturing control: 
The manufacturer, etc. must assure that the duties set forth 
below are carried out appropriately by the manufacturing 
department in compliance with standard operating 
procedures. 
 To prepare and preserve manufacturing instructions. 
 To manufacture products based on the manufacturing 
instructions. 
 To prepare and preserve records related to product 
manufacture fo r each lot.  
 To check packaging materials for products for each  lot, 
and to prepare and preserve records related to  the 
results thereof. 
 To appropriately store and circulate products by lot and 
packaging materials by control unit, and to prepare and 
preserve records thereof. 
 To check the cleaning of build ings and facilit ies, and to 
prepare and preserve records relating to the results 
thereof. 
 To inspect and maintain  build ings and facilities on a 
regular schedule, and to prepare and preserve records 
thereof. Further, to carry out appropriate calibration of 
measuring instruments, and to prepare and preserve 
records relating to the results thereof. 
 To check that manufacturing control has been 
appropriately conducted on the basis of records relating 
to manufacturing, storage and distribution, as well as to 
sanitation control. 
4) Quality control: 
 The manufacturer, etc. must assure that the duties set 
forth below are carried out systematically and 
appropriately by the quality department in compliance 
with standard operating procedures. 
 To collect  samples required for the testing and 
inspection of products, etc. for each lot and of 
packaging materials for each control unit, and to 
prepare and preserve records thereof. 
 To conduct testing and inspection of the samples 
collected for each lot or for each control unit, and to 
prepare and preserve records thereof. 
 To store samples of products consisting of an amount 
two or more t imes greater than the amount required for 
testing and inspection for each lot under appropriate 
storage conditions for a period of one year longer than 
the expiration period or the shelf-life from the date of 
manufacture fo r the product concerned. 
 To inspect and maintain on a regular schedule the 
facilit ies and implements relating to testing and 
inspection, and to prepare and preserve records thereof. 
Further to carry out appropriate calibrat ion of 
measuring instruments relating to testing and 
inspection, and to prepare and preserve records related 
to the results thereof. 
 To evaluate the test results of the samples collected, 
and to notify the manufacturing department in writ ing 
of the results thereof. 
 Further, manufacturers, etc. makes use of the tests and 
inspections performed in the import source country, 
they must assure that the quality department carries out 
the duties set forth below: 
 To confirm at on a regular schedule that that the 
product, etc. is manufactured in accordance with 
appropriate manufacturing procedures. 
 To confirm on a regular schedule that the 
manufacturing  plant of an overseas manufacturer 
conforms to the standards relating to manufacturing 
control and quality control in that country, and to 
prepare and preserve records thereof. 
 To confirm the records of tests and inspections carried 
out by the foreign manufacturer, and to prepare and 
preserve records thereof. 
5) Documents concerning procedures for validation:  
The manufacturer must prepare written procedures for 
validation change control, deviation control, complaints, 
recalls, self-inspections, training and education for each p lant 
so that these procedures can be performed appropriately.  
6) Validation: 
The manufacturer, etc. must ensure that the following 
obligations are fulfilled by a person designated beforehand in 
compliance with the standard operating procedures. 
 The validation plan  and results must be reported in writ ing 
to the quality control unit. The manufacturer, etc. must take 
appropriate measures when improvements are required in  
manufacturing control or quality control based on the results 
of the validation. Records of the measures taken must be 
prepared and retained. 
7) Change control: 
When manufacturers, etc. implement  changes with respect to 
manufacturing procedures, etc. that might affect the quality 
of the product, they must assure that a previously designated 
person carries out the duties set forth below, in compliance 
the standard operating procedures: 
 To evaluate the effect on product quality due to the 
changes and to obtain the consent of the quality 
department for implementation of changes based on the 
results of the evaluation. 
 When implementing the changes, to take measures for 
amendment of the relevant documentation, education 
and training of personnel, and any other requisite 
measures. 
8) Deviation control: 
When a deviation from the manufacturing procedures occurs, 
the manufacturer, etc. must assure that a previously 
designated person carries out the duties set forth below, in 
compliance with the standard operating procedures: 
 To record the details of the deviation. 
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 In cases where a major deviation has occurred, to 
evaluate the effect on product quality, to take requisite 
measures, to prepare and preserve the records, and to 
notify and obtain confirmation from the quality 
department. 
9) Information related to quality and handling quality 
defects: 
When the manufacturer, etc. acquires information relating to 
the quality, etc. of a drug, he must, except in cases in which 
it is clear that the items relating to the quality informat ion are 
not attributable to the manufacturing plant concerned, assure 
that a previously designated person carries out the duties set 
forth below, in compliance with the standard operating 
procedures, 
 To elucidate the causes of items relating to the quality 
informat ion concerned, and in cases in which 
improvements related to manufacturing control or 
quality control are required, to take the requisite 
measures. 
 To prepare and preserve a record specifying the nature 
of the quality information concerned, the results of the 
elucidation of causes, and the measures for 
improvement, and to promptly and in writing notify  
and obtain confirmat ion from the quality assurance 
department. 
 In cases in which  the manufacturer, etc. has identified a 
quality defect or the risk thereof, to assure that the 
manufacturing control manager notifies quality 
department in  writ ing on the basis of the standard 
operating procedures. 
10) Product recalls: 
When manufacturers decide to recall drugs for reasons 
related to quality, etc., they must assure that a previously 
designated person carries out the duties set forth below in 
compliance with the standard operating procedures. 
 To classify the recalled products and dispose of them 
appropriately after retention for a certain period. 
 To prepare and retain recall records including the 
contents of the recall, results of clarification of the 
cause and measures taken for improvement and notify  
the quality department and manufacturing control 
manager in writing thereof.  
11) Self-inspections: 
The manufacturer, etc. must have the following obligations 
fulfilled by a person designated beforehand in compliance 
with the standard operating procedures. 
 To undertake their own self-inspections of the 
manufacturing control and quality control in the plant 
concerned periodically. 
 To report the results of these self-inspections in writ ing 
to the manufacturing control manger.  
 To prepare and retain records of the results of self 
inspections. 
 The manufacturer must take appropriate measures 
when improvement is required in manufacturing 
control or quality control based on the results of the 
self-inspection. Records of the measures taken must be 
prepared and retained. 
12) Education and training: 
The manufacturer must have the fo llowing obligations 
fulfilled by a person designated beforehand in compliance 
with the standard operating procedures. 
 To systematically educate and train the workers in terms of 
manufacturing control and quality control. 
 To report the status of implementation of education and 
training in writing to the manufacturing control 
manager. 
 To prepared and retain records of the conduct of 
education and training. 
 To provide personnel engaged in manufacture or testing 
and inspection with education and training in hygiene 
control, microbio logy, and other matters requisite for 
the manufacture of sterile products. 
 The manufacturer shall provide education and train ing 
on microbiology, medicine and veterinary medicine for 
employees engaged in manufacture or testing of 
biological products. 
 The manufacturer shall provide education and train ing 
on the measures required to prevent contamination by 
microorganis ms for employees engaged in work in  
sterile areas or in areas handling pathogenic 
microorganis ms. 
13) Management of documents and records:  
The manufacturer, etc. must assure that, with respect to the 
documents and records specified under 1) through 12) above, 
a previously designated person.
18, 19, 20 
POST-MARKETING S URVEILLANCE OF DRUGS: 
 Post-market ing surveillance (PMS) to assure the efficacy 
and safety of drugs after they go on the market and to 
establish proper methods of use of drugs consists of three 
systems:  
  ADR collecting and reporting system 
  reexamination system, and 
  reevaluation system 
 
 ADR collecting and reporting system: Programs for 
collecting and reporting safety informat ion on drugs such as 
adverse drug reactions include an adverse drug reaction 
reporting system undertaken by pharmaceutical companies, 
the drug and medical device safety information reporting 
system undertaken by medical personnel, and the WHO 
International Drug Monitoring Program whereby drug safety 
informat ion is exchanged among various countries. 
 Reexamination system: The drugs subject to reexamination 
include products designated by the MHLW at the time of 
market ing approval as drugs with, for example, active 
ingredients, and quantities of ingredients, dosage and 
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administration, and/or indications that are distinctly different 
from drugs that have already been approved. 
 Reevaluation system: The reevaluation of drugs is a system 
whereby the efficacy  and safety of a drug, which has already 
been approved, is reconsidered on the basis of the current 
status of medical and pharmaceutical sciences.
21,22
 
 
MEDICAL INS URANCE S YS TEM:  
Japan provides a public medical insurance system, which is 
carried on as a social insurance system covering all citizens. 
Through this insurance system, about 30% of the nation’s 
medical expenses are covered by public funds, and all prices 
for medicine, including medical compensation for doctors 
and prices for new drugs are substantially  controlled  by the 
Japanese government. Recently, because the nation’s medical 
expenses are expected to increase along with the aging of 
Japanese society, policies for constraining the nation’s 
medical expenses have been adopted, which have 
significantly affected Japan’s pharmaceutical market.  
The Japanese government determines prices reimbursed by 
public medical insurance for each of preparat ions and 
standards of all drugs prescribed by doctors. The 
reimbursement price of each drug is reviewed every two 
years and almost all reimbursement prices of drugs are 
reduced, including those of new drugs immediately after 
their release onto the market.  
 This system is called the “Drug Pricing System” and under 
the system, expenses for d rugs covered by medical insurance 
are constrained and as a result, the size of the Japanese 
pharmaceutical market has been kept at a certain level in  
recent years. On the other hand, among major advanced 
nations, only Japan has a system in which the prices of new 
drugs immediately  after their release onto the market  are 
reduced through political act ion.
23
 
 
 
CONCLUS ION: 
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Japan has made significant progress in reforming and 
modernizing its drug and medical device approval process in 
recent years. Although approval times continue to lag  behind 
those of other developed countries, the government has set 
ambitious goals and the PMDA and MHLW have made 
marked  improvements. These gains, along with Japan’s 
position as the world’s second largest medical market, 
continue to make Japan a desirable p lace for foreign 
pharmaceutical companies and medical devices makers to  do 
business. 
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